ArticleInvestigative ophthalmology & visual science2026
PEDF Prevents Corneal Endothelial Dysfunction of Fuchs Endothelial Corneal Dystrophy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to explore the protection of pigment epithelium-derived factor (PEDF) on the corneal endothelium in Fuchs endothelial corneal dystrophy (FECD). Methods: PEDF levels in aqueous humor of FECD patients were quantified by enzyme-linked immunosorbent assay. PEDF receptor expression of corneal endothelium was validated by immunofluorescence staining and single-cell RNA sequencing datasets. In vitro cultured human corneal endothelial cells (HCECs) were treated with menadione (MN) alone or in combination with PEDF. Cellular viability, oxidative stress, mitochondrial membrane potential, adenosine triphosphate (ATP) production, mitochondrial DNA copy number, and mitochondrial bioenergetics were evaluated. The ultraviolet A (UVA)-induced FECD mouse model was employed to assess the protective effects of PEDF on corneal thickness and endothelial cell density, morphology, and functions. In addition, RNA sequencing, quantitative PCR, immunofluorescence staining, and automated simple western assay were performed to analyze the downstream signaling pathways of PEDF-treated HCECs. Results: Human and mouse corneal endothelial cells express PEDF receptor, but PEDF levels were significantly reduced in the aqueous humor of FECD patients. In cultured human corneal endothelial cells exposed to MN, PEDF effectively enhanced cellular viability, attenuated oxidative stress, and improved mitochondria-related functions. In the UVA-induced FECD mouse model, PEDF pretreatment prevented the decline of corneal endothelial cells and promoted the recovery of endothelial cell density, morphology, and functions. Mechanistically, the protective effects of PEDF were associated with the suppression of p53, TGF-β, and Hippo signaling pathways elevated in FECD. Conclusions: PEDF effectively prevents corneal endothelial dysfunction in FECD mouse and cellular models, highlighting its preclinical promise as a protective and therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.